【24h】

The advancements of heparanase in fibrosis

机译:乙酰肝素酶在纤维化中的研究进展

获取原文
           

摘要

Fibrosis is the endpoint in many chronic inflammatory diseases and is defined as an abnormal accumulation of extracellular matrix components. Fibrosis can affect almost any tissue, especially heart, lung, liver, and kidney, and numerous studies have been conducted to find satisfactory treatments. Since heparanase is a kind of endo-β-D-glucuronidase that is capable of cleaving heparan sulfate side chains of heparan sulfate proteoglycans on cell surfaces and the extracellular matrix, which further regulate the bioavailability of growth factors (FGF-2, TGF-β). Meanwhile, FGF-2 and TGF-β play a major role in the fibrosis process. Recent studies including ours have consistently demonstrated that heparanase could promote fibrosis process in different organs. Thus in this mini-review, we updated the advancement of heparanase in the regulation of fibrosis generation, and discussed its impact on several critical signaling pathways relevant to fibrosis.
机译:纤维化是许多慢性炎性疾病的终点,并且被定义为细胞外基质成分的异常积累。纤维化几乎可以影响任何组织,尤其是心脏,肺,肝和肾脏,因此进行了大量研究以找到令人满意的治疗方法。由于乙酰肝素酶是一种内切-β-D-葡萄糖醛酸酶,能够在细胞表面和细胞外基质上裂解硫酸乙酰肝素蛋白聚糖的硫酸乙酰肝素侧链,从而进一步调节生长因子(FGF-2,TGF-β )。同时,FGF-2和TGF-β在纤维化过程中起主要作用。包括我们在内的最新研究一致表明乙酰肝素酶可以促进不同器官的纤维化过程。因此,在本微型综述中,我们更新了乙酰肝素酶在纤维化生成调控中的进展,并讨论了其对与纤维化相关的几种关键信号通路的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号